Antibiotic

Norvancomycin is a glycopeptide antibiotic derived from Nocardia orientalis, exhibiting potent antibacterial activity against various strains of Staphylococcus aureus and Staphylococcus epidermidis. This compound is primarily utilized in infection research, providing insights into antibiotic resistance mechanisms and potential therapeutic interventions. Its efficacy in combating Gram-positive bacterial infections makes it a valuable tool for microbiological and pharmacological studies.

Monamycin G2 is an ester peptide antibiotic that primarily targets Gram-positive bacteria. This compound exhibits significant antibacterial activity, making it a valuable tool for research into antibiotic resistance and the mechanisms of bacterial infection. Its unique structure and function position Monamycin G2 as a promising candidate for further studies in antibiotic development and microbiological applications.

Dactimicin is a pseudodisaccharide aminoglycoside antibiotic that specifically inhibits bacterial protein synthesis. It is effective against methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci, demonstrating MIC50s of 2 μg/mL. Dactimicin retains activity against strains that produce aminoglycoside-modifying enzymes, making it a valuable reagent for research on antibiotic resistance and bacterial growth inhibition.

Saroaspidin B is an antibiotic compound featuring a dimeric structure derived from phloroglucinol. It exhibits significant antibacterial activity, making it a valuable reagent for studying microbial resistance and antibiotic efficacy. Research applications include investigating mechanisms of action against pathogenic bacteria and exploring potential therapeutic uses in infectious diseases.

Propeptin is a peptide antibiotic comprised of 19 amino acids, primarily targeting bacterial infections. It demonstrates selectivity by exhibiting weaker antibacterial activity against Pseudomonas aeruginosa, Mycobacterium monobacterium, and Xanthomonas oryzae. Although Propeptin does not affect KB and L1210 tumor cell lines, it effectively inhibits prolyl endopeptidase, suggesting potential applications in biochemical research and antibiotic development.

Sannamycin B is an aminoglycoside antibiotic that primarily targets bacterial ribosomes, inhibiting protein synthesis. While its antibacterial activity is limited to a few bacterial species, it serves as a valuable tool for studying antibiotic mechanisms and resistance. Sannamycin B can be utilized in research applications exploring the efficacy of aminoglycosides and the development of novel antimicrobial strategies.

Chrymutasin C is a glycosidic antibiotic known for its antitumor properties. It exerts cytotoxic effects on various cancer cell lines, making it a valuable compound for research applications in cancer treatment and drug development. Its efficacy in disrupting cellular processes highlights its potential as a therapeutic agent in oncology.

Cefpimizole sodium is a broad-spectrum cephalosporin antibiotic that targets bacterial cell wall synthesis. It is effective against a variety of Ampicillin-resistant bacteria and demonstrates significant activity against gram-negative species. In addition to its antimicrobial properties, cefpimizole sodium enhances the phagocytic activity of macrophages and neutrophils, making it valuable for research applications in microbiology and immunology.

(rac)-Methyl-6-gingerol is an antibiotic derived from Aframomum melegueta. This compound demonstrates significant anti-mycobacterial activity by inhibiting the efflux of toxins in Mycobacterium species. It serves as a valuable tool for research focused on combating mycobacterial infections and studying bacterial resistance mechanisms.

Seldomycin factor 5 is an aminoglycoside antibiotic with broad-spectrum antimicrobial activity. It disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to misreading of mRNA and subsequent inhibition of bacterial growth. Seldomycin factor 5 is utilized in research applications focused on bacterial resistance mechanisms and the development of new antimicrobial therapies.

Platenomycin W2 is a macrolide antibiotic that targets bacterial ribosomes to inhibit protein synthesis, specifically effective against Gram-positive bacteria. Its bioactivity makes it a valuable tool in studying bacterial resistance mechanisms and developing new therapeutic agents against infections caused by resistant strains. Researchers can utilize Platenomycin W2 in antimicrobial susceptibility assays and studies focused on the molecular pathways of antibiotic action.

Polymyxin B is an antibiotic that primarily targets Gram-negative bacteria by binding with high affinity to lipopolysaccharides (LPS) in the bacterial cell wall. This binding disrupts membrane integrity, leading to increased permeability and ultimately inducing bacterial cell death. Polymyxin B is extensively utilized in research related to endotoxemia due to its ability to neutralize endotoxins and mitigate their harmful effects.

Cefepime is a broad-spectrum cephalosporin antibiotic that effectively targets both Gram-positive and Gram-negative aerobic bacteria. It is characterized by its ability to penetrate the blood-brain barrier, making it suitable for treating central nervous system infections. While it exhibits potent antibacterial activity, it is important to note that cefepime has also been associated with neurotoxicity. This agent is utilized in various research applications focused on antibiotic resistance and infection control.

Trovafloxacin is a broad-spectrum quinolone antibiotic that primarily targets DNA gyrase and topoisomerase IV, exhibiting potent activity against Gram-positive, Gram-negative, and anaerobic bacteria. In addition to its antibacterial effects, Trovafloxacin is a selective inhibitor of the pannexin 1 channel (PANX1) with an IC50 of 4 μM, effectively modulating PANX1 inward current. Furthermore, Trovafloxacin influences cellular processes by inducing dysregulated fragmentation of apoptotic cells through PANX1 inhibition. This dual activity positions Trovafloxacin as a valuable reagent for research in microbiology and cell biology.

Cefoxitin is a cephalosporin-class antibiotic that exhibits strong stability against β-Lactamase. It demonstrates a broad spectrum of antibacterial activity, effective against both Gram-negative and Gram-positive bacteria. This compound is widely utilized in microbiological research and clinical studies focusing on antibiotic resistance and infection treatment.

Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, demonstrating potent activity against Gram-positive, Gram-negative, and anaerobic pathogens. Additionally, it serves as a selective and orally active inhibitor of the pannexin 1 channel (PANX1), with an IC50 of 4 μM for PANX1 inward current. Unlike other channels, Trovafloxacin mesylate does not affect connexin 43 gap junctions or PANX2, leading to potential therapeutic applications in the regulation of apoptosis by disrupting normal fragmentation of apoptotic cells through PANX1 inhibition.

G-418 is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the ribosomal subunits, affecting both eukaryotic and prokaryotic cells. Its potent antibacterial properties make it a valuable tool in research applications such as the selection and maintenance of genetically modified cells, allowing for the study of gene function and expression. G-418 is widely utilized in molecular biology and cell culture workflows.

Piperacillin is a semisynthetic broad-spectrum β-lactam antibiotic that exerts bactericidal activity against a range of Gram-negative bacteria and select Gram-positive strains by targeting penicillin-binding proteins. This compound is frequently utilized in combination with the β-lactamase inhibitor Tazobactam to enhance its efficacy in clinical applications, particularly for treating infections caused by resistant bacteria. Its extensive antimicrobial profile makes it valuable for research in infectious disease and antibiotic resistance.

Cefazolin is a first-generation cephalosporin antibiotic that targets bacterial cell wall synthesis, inhibiting bacterial growth. It exhibits significant antibacterial activity against various gram-positive and some gram-negative bacteria, making it useful in research on bacterial infections. Additionally, Cefazolin has demonstrated anti-inflammatory properties, indicating potential applications in studies related to post-operative cognitive dysfunction (POCD).

Fusidic acid is a bacteriostatic antibiotic derived from the fungus Fusidium coccineum, classified as a steroid. Its primary mechanism of action involves the inhibition of the release of translation elongation factor G (EF-G) from the ribosome, thereby suppressing bacterial growth. This compound is of particular interest in research focused on anticancer and anti-infective applications.

Pleuromutilin is a potent antibiotic that exerts its effects by inhibiting bacterial protein synthesis. This compound is effective against a variety of Gram-positive bacteria, making it a valuable tool in the study and treatment of antibiotic-resistant infections. Its specific mechanism of action targets the peptidyl transferase center of the ribosome, thereby disrupting essential bacterial cellular processes. Research applications include studies in microbiology, pharmacology, and infectious disease therapeutics.

Gramicidin S is a cationic cyclic peptide antibiotic that primarily targets bacterial cell membranes. It exhibits potent antibacterial activity by disrupting membrane integrity and inhibiting critical membrane protein functions, leading to cell death. The compound inserts into the phospholipid bilayer, specifically binding to negatively charged lipids, which interferes with cell division and wall synthesis. Additionally, Gramicidin S has been shown to inhibit ion channels, with IC50 values of 41 μM for Na+/K+-ATPase, 24 μM for tobacco leaf plasma membrane Mg2+/K+-ATPase, and 3 μM for rat heart plasma membrane Ca2+-ATPase, making it a valuable tool for research in microbiology and cell biology.

Lolamicin is an orally effective antibiotic that specifically targets the Gram-negative bacterial lipoprotein transport system, particularly the LolCDE complex. By competitively binding to lipoprotein binding sites, it inhibits the transmembrane transport of outer membrane lipoproteins, compromising the integrity of the bacterial outer membrane and resulting in cell death. Lolamicin demonstrates significant bactericidal and antibacterial activity against multidrug-resistant Enterobacteriaceae pathogens, including Escherichia coli and Klebsiella pneumoniae. This reagent is valuable for studying infections such as acute pneumonia and sepsis caused by Gram-negative bacteria.

Brilacidin tetrahydrochloride is a defensin mimetic antibiotic that exhibits potent antimicrobial activity against both Gram-positive and Gram-negative bacteria. It demonstrates minimum inhibitory concentrations (MIC90) of 1 μg/mL against Streptococcus pneumoniae and 8 μg/mL against Streptococcus viridans, alongside MIC90 values of 8 μg/mL for Haemophilus influenzae and 4 μg/mL for Pseudomonas aeruginosa. This compound is particularly valuable in microbiological research and the development of novel therapeutic strategies for bacterial infections.

Ertapenem disodium is a broad-spectrum β-lactam antibiotic known for its long-lasting activity against a wide range of pathogens. It exhibits significant anti-anaerobic efficacy, with a minimum inhibitory concentration (MIC) of 0.12 μg/mL against various anaerobic bacteria. This reagent is particularly useful in research focused on severe infections affecting the skin, lungs, stomach, pelvis, and urinary tract.

SPR206 acetate is a polymyxin analog that exhibits potent antibiotic activity against Gram-negative pathogens, including multidrug-resistant strains. Its mechanism involves disrupting the outer membrane of bacteria, leading to bactericidal effects. SPR206 acetate demonstrates low minimum inhibitory concentration (MIC) values of 0.125 mg/L against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301, making it a valuable tool in the study of bacterial infections and antibiotic resistance.

Trimethoprim lactate is a bacteriostatic antibiotic that functions as a dihydrofolate reductase inhibitor. It exhibits activity against a broad spectrum of Gram-positive and Gram-negative aerobic bacteria, making it valuable in research related to urinary tract infections, Shigellosis, and Pneumocystis pneumonia. Additionally, Trimethoprim lactate has been shown to inhibit Influenza A virus infection in chick embryos when used in combination with zinc.

Cefuroxime is a second-generation cephalosporin antibiotic that exerts its effects through inhibition of bacterial cell wall synthesis. It demonstrates a broad-spectrum efficacy against both Gram-positive and Gram-negative bacteria while exhibiting enhanced stability to β-lactamase enzymes. Cefuroxime is widely utilized in research applications aimed at studying bacterial infections and antibiotic resistance.

Amikacin sulfate is an aminoglycoside antibiotic and a semisynthetic derivative of kanamycin, primarily targeting bacterial ribosomal subunits 30S and 50S to inhibit protein synthesis. This compound exhibits potent bactericidal activity against a wide range of Gram-negative bacteria, including strains resistant to gentamicin and tobramycin. Additionally, amikacin sulfate is effective against infections caused by susceptible Nocardia and nontuberculous mycobacteria, making it valuable in various microbiological research applications.

Colominic acid sodium salt is a polysaccharide derived from the cell wall of Escherichia coli and various animal sources. This compound exhibits antibacterial activity and is characterized by a distinctive red color, with an absorption maximum at 530 nm. It serves as a valuable tool in microbiological research, particularly for studying bacterial interactions and polysaccharide functions in biological systems.

Cephaloridine hydrate is a broad-spectrum antibacterial antibiotic that targets bacterial cell wall synthesis. It exhibits significant antibacterial activity against a variety of gram-positive and gram-negative organisms. Although effective, it is important to note that cephaloridine has been associated with dose-related nephrotoxicity, which should be considered in experimental applications.

Plazomicin sulfate is a semi-synthetic aminoglycoside antibiotic that primarily targets bacterial ribosomes to disrupt protein synthesis. It functions as a substrate for aminoglycoside acetyltransferase and aminoglycoside phosphotransferase while remaining unmodified by several common aminoglycoside-modifying enzymes. Plazomicin sulfate exhibits selective inhibition of MATE2-K and demonstrates significant efficacy against multidrug-resistant bacteria, including carbapenem-resistant Enterobacterales. This compound is valuable for research applications focusing on antibiotic resistance and the mechanisms of action of aminoglycosides.

Dalfopristin is a semisynthetic sulfone antibiotic that functions by inhibiting bacterial protein synthesis. Although Dalfopristin exhibits limited antibacterial activity on its own, it demonstrates significant bactericidal effects in synergy with Quinupristin, particularly against a range of pathogenic Gram-positive cocci. This compound is utilized in research focused on antibiotic resistance and the development of combination therapies for bacterial infections.

Cefquinome sulfate is a broad-spectrum cephem antibiotic that targets bacterial cell wall synthesis, effectively inhibiting a wide range of Gram-positive and Gram-negative bacteria. Its antibacterial activity extends to species such as Staphylococci, Streptococci, Pseudomonas, and Enterobacteriaceae. Cefquinome sulfate is primarily used in veterinary medicine for the treatment of bacterial infections, making it a valuable tool in microbiological research and antibiotic susceptibility studies.

SPR741 is a cationic peptide antibiotic derived from polymyxin B, functioning primarily as a potentiator. It enhances the permeability of the outer membrane in Gram-negative bacteria, making it an effective agent against multidrug-resistant strains. SPR741 is utilized in research focused on severe Gram-negative infections and can broaden the spectrum of activity when used in combination with other antibiotics.

Nalidixic acid sodium salt is a quinolone antibiotic targeting DNA gyrase and topoisomerase IV. It exhibits bacteriostatic activity at lower concentrations and becomes bactericidal at higher concentrations, effectively inhibiting DNA replication in susceptible gram-positive and gram-negative bacteria. This compound is valuable for microbiological research and antibiotic susceptibility testing, facilitating the study of bacterial infections and resistance mechanisms.

Nosiheptide is a thiopeptide antibiotic that targets bacterial protein synthesis. It is produced by Streptomyces actuosus and features a unique indole side ring system along with regiospecific hydroxyl groups on its macrocyclic core. Nosiheptide is utilized in research applications focused on antimicrobial activity and has also been used as a feed additive to promote animal growth.

Lefamulin acetate is an orally active antibiotic that targets bacterial protein synthesis by binding to the peptidyl transferase center of the 50S ribosomal subunit. This mechanism disrupts bacterial growth and has been shown to possess anti-inflammatory properties. Lefamulin acetate is applicable in research focused on bacterial infections, including those caused by pneumonia-inducing pathogens.

Virginiamycin M1 is a polyunsaturated macrocyclic lactone antibiotic derived from Streptomyces virginiae. It exhibits significant antibacterial activity against Staphylococcus aureus, with a minimal inhibitory concentration (MIC) of 0.25 μg/mL. This compound is commonly utilized in research applications to investigate antibiotic mechanisms and resistance, as well as for the study of bacterial pathogens.

Framycetin sulfate, an aminoglycoside antibiotic, primarily targets RNase P, functioning as a potent inhibitor of its cleavage activity with a Ki of 35 μM. It competes for divalent metal ion binding sites within RNase P RNA, effectively inhibiting the hammerhead ribozyme with a Ki of 13.5 μM. Additionally, as a 5″-azido neomycin B precursor, Framycetin sulfate binds to the Drosha site in miR-525, making it applicable in the study of hepatic encephalopathy and enteropathogenic E. coli infections.

Nemadectin is an orally active broad-spectrum endectocide that targets gastrointestinal helminths. It demonstrates potent anthelmintic activity, making it effective against natural infections in canines caused by major helminth species. This compound is valuable for research applications focused on parasitic infections and the development of novel anthelmintic therapies.

Kanamycin sulfate is a broad-spectrum aminoglycoside antibiotic that primarily targets bacterial protein synthesis by binding to the 30S ribosomal subunit. This reagent is effective against a range of bacterial infections, particularly those caused by certain staphylococci and Gram-negative bacilli. However, caution is advised due to its potential ototoxic effects. Kanamycin sulfate is commonly utilized in microbiological research and treatment protocols for severe bacterial infections.

Cefpodoxime is a broad-spectrum antibiotic that exhibits activity against a variety of gram-positive and gram-negative bacteria. Its primary mechanism of action involves inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Cefpodoxime is useful for research applications related to acute otitis media, sinusitis, and tonsillopharyngitis, enabling investigations into microbial resistance and treatment efficacy.

Demeclocycline is an orally active tetracycline antibiotic that targets bacterial protein synthesis. It functions by binding to the 30S ribosomal subunit, effectively inhibiting the binding of aminoacyl-tRNA. Demeclocycline demonstrates antibacterial activity against a broad spectrum of bacterial infections and is utilized in various research applications related to antibiotic resistance and microbial pathogenesis.

Gentamicin C1a is an aminoglycoside antibiotic that primarily targets bacterial ribosomes, inhibiting protein synthesis. As the major component of the Gentamicin complex, it exhibits significant antibacterial activity against a wide range of Gram-negative and some Gram-positive bacteria. Gentamicin C1a is commonly employed in microbiological research and clinical studies to evaluate antibacterial efficacy and resistance mechanisms.

Cloxacillin sodium is a β-lactam antibiotic and a potent β-lactamase inhibitor with an IC50 of 0.04 µM. It exhibits significant antibacterial activity, particularly against Staphylococcus aureus, and can effectively attenuate the S. aureus-induced inflammatory response by inhibiting the activation of MAPK, NF-κB, and NLRP3-related proteins. This compound is relevant for research in antimicrobial resistance and inflammation pathways.

Lefamulin is an orally active antibiotic that primarily targets bacterial protein synthesis by binding to the peptidyl transferase center of the 50S ribosomal subunit. This binding effectively inhibits the formation of peptide bonds, leading to disruption of bacterial growth. In addition to its antimicrobial properties, Lefamulin exhibits anti-inflammatory activity. It is valuable for research applications focused on bacterial infections, including conditions such as bacterial pneumonia.

Amoxicillin-clavulanate potassium is a combination antibiotic that targets bacterial cell wall synthesis and inhibits beta-lactamase enzymes. It exhibits broad-spectrum antibacterial activity against a variety of Gram-positive and Gram-negative pathogens. This reagent is commonly utilized in research to study bacterial infections and evaluate potential therapeutic strategies for combating antibiotic resistance.

Contezolid is an orally active oxazolidinone antibiotic targeting resistant Gram-positive bacteria. It demonstrates significant efficacy against complicated skin and soft tissue infections (cSSTI) while exhibiting a reduced risk of myelosuppression and minimal monoamine oxidase inhibition. This unique profile makes Contezolid a promising candidate for the treatment of infections caused by resistant strains.

Mupirocin lithium is an antibiotic that targets bacterial isoleucyl-tRNA synthetase, effectively inhibiting protein synthesis. This compound exhibits potent activity against a range of Gram-positive bacteria, including Staphylococcus and Streptococcus, as well as certain Gram-negative strains such as Haemophilus influenzae. Mupirocin lithium is utilized in research focused on skin infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA), and chronic sinusitis.